Neurogene Inc.
NASDAQ:NGNEBiotechnology
Healthcare
$23.14 +2.47%
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
52W Low $14.65High $37.27
Volume 0.25M
Average 0.16M
Balance Sheet
Inspect the capital base behind the business.
Assets
$288.60M
FY 2025 · Annual
-14.0% YoYLiabilities
$23.72M
FY 2025 · Annual
-6.5% YoYEquity
$264.89M
FY 2025 · Annual
-14.7% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70.54M | 82.02M | 148.21M | 136.59M | 103.85M |
| Short-term Investments | 0 | 0 | 48.95M | 175.82M | 165.17M |
| Net Receivables | 790K | 0 | 600K | 648K | 0 |
| Inventory | 1.91M | 0 | 0 | 0 | 0 |
| Other Current Assets | (1.2M) | 1.62M | 1.1M | 981K | 2.76M |
| Total Current Assets | 73.96M | 84.72M | 200.35M | 315.92M | 271.77M |
| Property, Plant & Equipment (Net) | 27.53M | 24.55M | 20.95M | 18.49M | 15.46M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 128K | 0 | 0 | 0 | 0 |
| Long-term Investments | 878K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1.01M) | 0 | 1.27M | 1.31M | 1.37M |
| Total Non-current Assets | 27.53M | 24.55M | 22.23M | 19.81M | 16.83M |
| Total Assets | 101.49M | 109.27M | 222.57M | 335.73M | 288.6M |
| Account Payables | 5.63M | 625K | 2.6M | 1.34M | 1.95M |
| Short-term Debt | 1.22M | 0 | 0 | 3M | 3.06M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 132K | 167K | 6.71M | 1.43M | 6.32M |
| Total Current Liabilities | 10.86M | 6.65M | 22.97M | 15.16M | 16.41M |
| Long-term Debt | 0 | 0 | 0 | 0 | 6.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 177.91M | 0 | 203K | 769K | 479K |
| Total Non-current Liabilities | 182.51M | 3.99M | 13.58M | 10.2M | 7.31M |
| Total Liabilities | 193.36M | 10.64M | 36.55M | 25.36M | 23.72M |
| Common Stock | 1K | 0 | 0 | 0 | 0 |
| Retained Earnings | (95.65M) | (150.84M) | (187.15M) | (262.3M) | (352.65M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (91.88M) | 98.63M | 186.02M | 310.38M | 264.89M |
| Total Debt | 6.43M | 4.69M | 16.26M | 12.43M | 9.89M |
| Net Debt | (64.11M) | (77.33M) | (131.96M) | (124.16M) | (93.95M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $124.2M |
| Short-term Investments | $119.0M |
| Other Current | $3.6M |
| Total Current Assets | $246.7M |
| PP&E (Net) | $15.0M |
| Other Non-current | $1.4M |
| Total Non-current Assets | $16.4M |
| Total Assets | $263.1M |
Analysis
Selected assets total $263.1M for Latest. The largest visible component is Cash & Equivalents at $124.2M, about 47.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 | |
| SC 13G | SC 13G filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
How much cash does NGNE have?
Neurogene Inc. (NGNE) reported $103.84M in cash and equivalents in fiscal 2025.
How much debt does NGNE carry?
Neurogene Inc. (NGNE) reported $9.89M of total debt, with net debt of -$93.95M.
Continue the stock analysis
Jump to another research area for this company.